Cargando…
Exome array analysis of adverse reactions to fluoropyrimidine-based therapy for gastrointestinal cancer
Fluoropyrimidines, including 5-fluororacil (5FU) and its pro-drug Capecitabine, are the common treatment for colorectal, breast, neck and head cancers—either as monotherapy or in combination therapy. Adverse reactions (ADRs) to the treatment are common and often result in treatment discontinuation o...
Autores principales: | Traylor, Matthew, Walker, Jemma L., Corrigan, Adele A., Hernandez, Monica A., Newhouse, Stephen J., Folarin, Amos A., Patel, Hamel, Ross, Paul J., Sanderson, Jeremy D., Spicer, James, Prescott, Natalie J., Mathew, Christopher G., Marinaki, Anthony M., Lewis, Cathryn M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929530/ https://www.ncbi.nlm.nih.gov/pubmed/29715290 http://dx.doi.org/10.1371/journal.pone.0188911 |
Ejemplares similares
-
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity
por: Loganayagam, A, et al.
Publicado: (2013) -
Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer
por: Punt, C.J.A., et al.
Publicado: (2023) -
Fluoropyrimidine-induced cardiotoxicity
por: Deac, Andrada Larisa, et al.
Publicado: (2020) -
DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach
por: Villalvazo, Priscila, et al.
Publicado: (2021) -
An exome array study of the plasma metabolome
por: Rhee, Eugene P., et al.
Publicado: (2016)